Los Angeles Capital Management
CRNX icon

Los Angeles Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Los Angeles Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$357K Sell
9,821
-1,446
-13% -$64.6K ﹤0.01% 976
2025
Q4 		$488K Buy
11,267
+1,834
+19% +$81.6K ﹤0.01% 900
2025
Q3 		$393K Hold
9,433
– – ﹤0.01% 1021
2025
Q2 		$271K Buy
+9,433
New +$291K ﹤0.01% 1091

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Los Angeles Capital Management's CRNX Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Crinetics Pharmaceuticals (CRNX) stake by 13% in Q1 2026, selling an estimated $64.6K and leaving 9,821 shares worth $357K. The position accounts for ﹤0.01% of the portfolio, ranked #976.

Los Angeles Capital Management first reported a position in CRNX in Q2 2025 and has held it in 4 quarters since. The position peaked at $488K in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Los Angeles Capital Management held 9,821 shares of Crinetics Pharmaceuticals worth $357K as of Q1 2026.
  • Los Angeles Capital Management sold 1,446 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $64.6K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #976 holding.
  • Los Angeles Capital Management first reported a position in Crinetics Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Los Angeles Capital Management's Crinetics Pharmaceuticals position peaked at $488K in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.